Breakthrough review unveils molecular mechanisms and emerging therapies for sarcopenia in aging populations
FAR Publishing Limited
A groundbreaking review published in Current Molecular Pharmacology sheds light on sarcopenia, a debilitating age-related muscle loss affecting millions globally. The study, led by Priyanka Prajapati and colleagues, delves into the pathophysiology, highlighting oxidative stress, mitochondrial dysfunction, and hormonal imbalances as key drivers.
"Sarcopenia isn’t just about muscle loss—it’s a complex interplay of metabolic and inflammatory pathways," explained Prajapati. The review identifies promising interventions, including resistance training, leucine supplementation, and vitamin D, which enhance muscle protein synthesis and reduce inflammation. Notably, hormone therapies like testosterone and growth hormone show potential in reversing muscle atrophy.
The team also emphasizes nutraceuticals like omega-3 fatty acids and polyphenols for their anti-inflammatory and antioxidant properties. "Combining pharmacological and lifestyle interventions could offer a holistic approach," added co-author Anand Kumar. With sarcopenia’s global prevalence rising, this review paves the way for targeted therapies to improve elderly quality of life.
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.